American Academy of Ophthalmology Meeting

NEW ORLEANS ― At the American Academy of Ophthalmology meeting here, Savak “Sev” Teymoorian, MD, MBA, discusses a survey of adjunctive glaucoma therapy prescribing by ophthalmologists that shows the majority prescribe twice a day as opposed to the labeled three times daily treatment. The study found adherence and patient quality of life were the main factors.

NEW ORLEANS ― At the American Academy of Ophthalmology meeting here, J. Bradley Randleman, MD, of the USC Roski Eye Institute, discusses his research into diagnosing asymmetric keratoconus in patients using Scheimpflug and OCT imaging.

NEW ORLEANS ― At the American Academy of Ophthalmology meeting here, David Gossage, DO, shares pearls on how to use MicroPulse technology (Iridex) for glaucoma and retina treatments.

NEW ORLEANS — A dose of intravitreal bevacizumab as low as 0.031 mg was successful in treating acute, severe retinopathy of prematurity in a small cohort of infant patients, a speaker said here.

NEW ORLEANS ― At the American Academy of Ophthalmology meeting here, David B. Samimi, MD, of the USC Roski Eye Institute, discusses newer minimally invasive lower eyelid surgery techniques for better aesthetic outcomes

NEW ORLEANS ― At the American Academy of Ophthalmology meeting here, Nathan Radcliffe, MD, of New York Eye and Ear, discusses his implementation of the Allergan Xen gel stent for treating patients with refractory glaucoma or those in need of a minimally invasive glaucoma procedure to lower IOP. 

NEW ORLEANS — Data from two studies reinforce the finding that intranasal tear neurostimulation results in significantly increased acute tear production compared with either active extranasal or sham intranasal applications, a speaker said.

NEW ORLEANS ― At the American Academy of Ophthalmology meeting here, Amar Agarwal, MS, FRCS, FRCOphth, discusses the single-pass, four-throw pupilloplasty technique he has been using in narrow-angle and closed-angle glaucoma cases to drastically lower IOP.

NEW ORLEANS — All doses and strengths of Allergan’s bimatoprost sustained release implant demonstrated efficacy in patients with open-angle glaucoma, E. Randy Craven, MD, said at the American Academy of Ophthalmology meeting.

NEW ORLEANS ― At the American Academy of Ophthalmology meeting here, Nathan C. Steinle, MD, discusses the RADIANCE trial comparing Lucentis (ranibizumab, Genentech) vs. photodynamic therapy for myopic choroidal neovascular membrane.